A new version of a combination drug marketed by Roche for early-stage and metastatic breast cancer with a specific genetic signature received FDA approval Monday for a formulation that can be delivered in minutes rather than an hour or more.
The... Read more »
Heron Therapeutics revealed Monday that its investigational non-opioid drug for treating postoperative pain has again been rejected by the FDA.
The San Diego company’s HTX-011 is an extended-release solution of bupivacaine, a local anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug. Heron... Read more »
Creating cell therapies for cancer is a complex process. The business case for them has proven tricky, too.
Biotech veterans Tom Farrell and Peter Flynn have teamed up to start a new San Diego company that aims to develop allogeneic, or... Read more »
Uncertainty related to the continued spread of the pandemic continued to consume most of the oxygen in the room this week, but life sciences news outside of that arena continued apace.
Once considered all but shuttered, the IPO market again saw... Read more »
It’s common for antibiotics developers to run into financial trouble these days but what’s unusual is seeing a bidding war erupt for one of them. The competition for Tetraphase Pharmaceuticals now has a new winner: La Jolla Pharmaceutical.
San Diego-based... Read more »
Reneo Pharmaceuticals has encouraging results from an early trial of a compound it is advancing for rare diseases characterized by impaired mitochondria—our cells’ energy generators—and the company says it is now designing a large global study of its drug candidate.
Headed... Read more »
The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on pharmaceutical products spanning the entire sector.
Royalty Pharma (NASDAQ: RPRX) acquires the royalty rights... Read more »
Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential therapies.
Engrail Therapeutics, which emerged from stealth Thursday with $32 million in outside financing, landed its entire... Read more »
Lassen Therapeutics, a biotech that is developing antibodies as potential treatments for fibrosis, rare diseases, and cancer, debuted Wednesday with $31 million in Series A financing.
The San Diego-based company says it will use the money to accelerate its antibody programs,... Read more »
Gene sequencing company Pacific Biosciences of California is seeking two new leaders in the wake of retirement announcements by a pair of longtime top executives.
PacBio (NASDAQ: PACB) president and CEO Michael Hunkapiller plans to retire by year’s end, and... Read more »
The FDA on Monday revoked its emergency authorization permitting use of the antimalarial drugs hydroxychloroquine and chloroquine to treat the novel coronavirus, citing a lack of evidence of their efficacy.
In late March the agency authorized the drugs, which President Donald... Read more »
At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization.
Instead, attendees from 64 countries spanning 28 times zones convened online this week... Read more »
Less than a month after reporting preliminary early-stage data for its experimental vaccine for the novel coronavirus, Moderna has finalized the plan for a Phase 3 test.
The study, set to begin next month, is targeting enrollment of about 30,000 volunteers,... Read more »
Hearing loss can stem from a variety of reasons, but in rare cases it’s caused by genetic defects. Akouos is developing a gene therapy to address these problems and it’s planning an IPO to finance the first tests of its approach... Read more »
Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Disease doesn’t discriminate by race, but health and economic disparities put some groups at higher risk than others. And yet clinical trials fail to reflect... Read more »
An AbbVie drug that treats pain in the uterus has notched an additional FDA approval for addressing heavy menstrual bleeding associated with uterine fibroids.
The regulatory decision Friday covers that drug, elagolix, combined with estrogen and progestin in a capsule that... Read more »
A year ago about 40,000 people gathered in Chicago for the annual meeting of the American Society of Clinical Oncology. Today a virtual version of the ASCO conference, the cancer field’s largest, kicks off, with oncologists and others tuning in from... Read more »
Xconomy Insight is excited to offer two special webinars to our community this June. Sponsored by Eurofins, registration is free to all.
Applying Cell-based In Vitro Assays to Improve In Vitro Hepatotoxicity Assessment Challenges
Date: Wednesday, June 10, 2020
... Read more »
Privately held biotech ViaCyte has banked $27 million, the majority an installment of cash from a tranched $80 million Series D financing round it closed in late 2018. The company says the money will go to further develop the three diabetes... Read more »
COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list... Read more »
While treatments for many health conditions have undergone reinvention in the past two decades, birth control options haven’t changed much. On Friday, San Diego-based Evofem Biosciences said it received FDA approval for a new kind of contraceptive: a non-hormonal vaginal gel... Read more »
As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything resembling a pre-pandemic normal without a COVID-19 vaccine.
Moderna (NASDAQ: MRNA... Read more »
Sponsored · Whitepaper
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
IBM Watson
Sponsored · Whitepaper
Leveraging technology & expertise to ensure a continual journey from trials to treatments
PRA Health Sciences
Sponsored · Webinar
In vitro assays that tackle the challenges of in vitro hepatotoxicity assessment
Eurofins Discovery
